According to
GuruFocus Insider Data
, these are the largest CEO buys during the past week. The
overall trend of CEOs is illustrated in the chart below:
Utd Therapeutic (
UTHR
): CEO Martine A Rothblatt Bought 31,368 Shares
CEO of Utd Therapeutic (
UTHR
) Martine A Rothblatt bought 31,368 shares during the past week
at an average price of $47.78. UTD THERAPEUTIC is a biotechnology
company focused on combating cardiovascular, inflammatory, and
infectious diseases with unique therapeutic products. Utd
Therapeutic has a market cap of $2.32 billion; its shares were
traded at around $47.78 with a P/E ratio of 9.8 and P/S ratio of
3.1.
Total revenues for the quarter ended March 31, 2012 were $204.2
million, up from $162.5 million for the quarter ended March 31,
2011. Net income for the quarter ended March 31, 2012 was $70.8
million or $1.32 per basic share, compared to $16.4 million or
$0.28 per basic share for the same quarter in 2011. Gross margin
from sales was $178.9 million for the quarter ended March 31,
2012, compared to $142.5 million for the same quarter last year.
Earnings before non-cash charges(1) for the quarter ended March
31, 2012 were $114.4 million, compared to $80.7 million for the
quarter ended March 31, 2011.
Richard Perry
bought 15,300 shares in the quarter that ended on 03/31/2012,
which is 0.035% of the $2.08 billion portfolio of Perry Capital.
Joel Greenblatt
owns 165,063 shares as of 03/31/2012, an increase of 82.68% from
the previous quarter. This position accounts for 0.68% of the
$1.15 billion portfolio of Gotham Capital.
Edward Owens
owns 1,787,000 shares as of 03/31/2012, which accounts for 0.4%
of the $20.91 billion portfolio of Vanguard Health Care Fund.
Director Christopher Patusky sold 2,500 shares of UTHR stock on
04/04/2012 at the average price of 45.55. Christopher Patusky
owns at least 1,300 shares after this. The price of the stock has
increased by 4.9% since. Other insiders have also decreased their
positions in the company.
Transatl Petrol (
TAT
): CEO, 10% Owner Noah Malone Mitchell Iii Bought 456,394
Shares
CEO, 10% Owner of Transatl Petrol (
TAT
) Noah Malone Mitchell Iii bought 456,394 shares during the past
week at an average price of $0.99. TransAtlantic Petroleum Ltd.
is a vertically integrated, international oil and gas company.
Transatl Petrol has a market cap of $358.8 million; its shares
were traded at around $0.99 with and P/S ratio of 2.8.
Transatlantic Petrol recently reported its second quarter 2012
results. The company reported revenues of $1.2 billion, compared
with $1.1 billion for the second quarter of 2011. Net loss was
$13.2 million, compared with $8.7 million in 2011.
COO Mustafa Yavuz bought 7,409 shares of TAT stock on 06/12/2012
at the average price of 1. Mustafa Yavuz owns at least 7,409
shares after this.
Pharmerica Corp (
PMC
): CEO Gregory S Weishar Bought 35,500 Shares
CEO of Pharmerica Corp (
PMC
) Gregory S Weishar bought 35,500 shares on 06/14/2012 at an
average price of $10.18. PharMerica Corporation is an
institutional pharmacy services provider dedicated to providing
quality customer service and innovative pharmacy solutions to
institutional customers and patients in long-term care settings.
Pharmerica Corp has a market cap of $287.9 million; its shares
were traded at around $10.18 with a P/E ratio of 7.3 and P/S
ratio of 0.1. Pharmerica Corp had an annual average earnings
growth of 18.6% over the past 5 years.
Phamerica recently reported its first quarter 2012 financial
results. Revenues were $498.9 million, compared to $535.1 million
in the first quarter of 2011. Gross profit for the first quarter
2012 was $72.6 million, compared to $66.1 million in the first
quarter of 2011.
HOTCHKIS & WILEY owns 768,800 shares as of 03/31/2012, which
accounts for 0.057% of the $16.79 billion portfolio of Hotchkis
& Wiley Capital Management LLC. Jean-Marie Eveillard sold out
his holdings in the quarter that ended on 03/31/2012.
EVP and CFO Michael J Culotta bought 15,000 shares of PMC stock
on 06/14/2012 at the average price of 9.51. Michael J Culotta
owns at least 158,208 shares after this. The price of the stock
has increased by 7.05% since. Other insiders have also increased
their positions in the company.
Brocade Comm Sy (
BRCD
): CEO Michael Klayko Bought 60,000 Shares
CEO of Brocade Comm Sy (
BRCD
) Michael Klayko bought 60,000 shares on 06/13/2012 at an average
price of $4.79. Brocade Communications Systems, Inc. delivers
industry-platforms, solutions, and services for intelligently
connecting, managing, and optimizing IT resources in shared
storage environments. Brocade Comm Sy has a market cap of $2.14
billion; its shares were traded at around $4.79 with a P/E ratio
of 12.6 and P/S ratio of 1. Brocade Comm Sy had an annual average
earnings growth of 15.3% over the past 10 years. GuruFocus rated
Brocade Comm Sy the business predictability rank of 2-star.
BRCD recently reported financial results for its second fiscal
quarter ended April 28, 2012. Brocade reported second quarter
revenue of $543.4 million, representing a decrease of 1%
year-over-year and 3% quarter-over-quarter and resulting in
diluted earnings per share of $0.08 on a GAAP basis and diluted
earnings per share of $0.15 on a non-GAAP basis, up 58% and 24%
year-over-year, respectively.
David Dreman bought 4,141,969 shares in the quarter that ended on
03/31/2012, which is 0.5% of the $4.79 billion portfolio of
Dreman Value Management. Ray Dalio owns 543,135 shares as of
03/31/2012, an increase of 1579.71% from the previous quarter.
This position accounts for 0.049% of the $6.43 billion portfolio
of Bridgewater Associates. Joel Greenblatt owns 243,087 shares as
of 03/31/2012, an increase of 123.38% from the previous quarter.
This position accounts for 0.12% of the $1.15 billion portfolio
of Gotham Capital.
CFO, VP of Finance Daniel W Fairfax sold 20,378 shares of BRCD
stock on 03/23/2012 at the average price of 5.65. Daniel W
Fairfax owns at least 218,123 shares after this. The price of the
stock has decreased by 15.22% since. Other insiders have also
decreased their positions in the company.
Endo Pharmaceut (
ENDP
): President & CEO David Holveck Bought 8,550 Shares
President & CEO of Endo Pharmaceut (
ENDP
) David Holveck bought 8,550 shares on 06/12/2012 at an average
price of $30.13. Endo Pharmaceuticals Holdings Inc., through its
wholly owned subsidiaries, Endo Pharmaceuticals Inc. Endo
Pharmaceut has a market cap of $3.5 billion; its shares were
traded at around $30.13 with a P/E ratio of 6.5 and P/S ratio of
1.3. Endo Pharmaceut had an annual average earnings growth of
31.7% over the past 10 years. GuruFocus rated Endo Pharmaceut the
business predictability rank of 3.5-star.
Joel Greenblatt bought 17,025 shares in the quarter that ended on
03/31/2012, which is 0.057% of the $1.15 billion portfolio of
Gotham Capital. Lee Ainslie owns 5,508,833 shares as of
03/31/2012, an increase of 86.23% from the previous quarter. This
position accounts for 3.1% of the $6.95 billion portfolio of
Maverick Capital. David Dreman owns 92,625 shares as of
03/31/2012, which accounts for 0.075% of the $4.79 billion
portfolio of Dreman Value Management. John Hussman owns 1,914,000
shares as of 03/31/2012, which accounts for 1.4% of the $5.16
billion portfolio of Hussman Economtrics Advisors.About
GuruFocus: GuruFocus.com tracks the stocks picks and portfolio
holdings of the world's best investors. This value investing site
offers stock screeners and valuation tools. And publishes daily
articles tracking the latest moves of the world's best investors.
GuruFocus also provides promising stock ideas in 3 monthly
newsletters sent to
Premium Members
.